Revaprazan

Drug Profile

Revaprazan

Alternative Names: Revanex; SB 641257; YH 1885; YH1885L

Latest Information Update: 03 Feb 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yuhan
  • Class Antiulcers; Isoquinolines; Small molecules
  • Mechanism of Action Potassium-competitive acid blockers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Duodenal ulcer; Gastric ulcer; Gastritis
  • No development reported Gastro-oesophageal reflux

Most Recent Events

  • 03 Feb 2016 No recent reports on development identified - Phase-II for Gastro-oesophageal reflux in South Korea (PO)
  • 01 Apr 2014 Yuhan Corporation completes a phase II trial in non-erosive Gastro-oesophageal reflux in South Korea (NCT01750437)
  • 15 Jul 2013 Yuhan Corporation completes enrolment in a phase II trial for non-erosive Gastro-oesophageal reflux in South Korea (NCT01750437)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top